MARKETS / NYSE / AORT
NYSE · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP

Artivion, Inc. AORT

17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY3 YEARS OF DIVIDEND GROWTH
Revenue · FY2025
$441.3M
▲ 13.6% vs FY2024
Dividend streak
3 yrs
Raised every year since 2023
EPS · FY25
$0.21
Dividend / sh · FY25
Payout · FY25
ROE · FY25
2.7%
Net margin · FY25
2.2%
Dividend coverage
1.2×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 441.3M
Revenue, FY2025 · full 17-year series below
Revenue Net income
0.20.40.60.40.02009201220152018202120242025
0.20.40.60.40.02016201920222025

2 cents of every revenue dollar became profit this year.

Per share
USD 0.21
Diluted EPS, FY2025
EPS Dividend
0.40.81.20.212009201220152018202120242025
0.40.81.20.212016201920222025

Earnings covered the dividend 1.2 times — the rest stayed in the company.

Profitability
2.7%
Return on equity, FY2025
ROE
48122.7%2009201220152018202120242025
48122.7%2016201920222025
Operating margin7.6%
Net margin2.2%
Return on assets1.2%

Each USD of equity produced 3 cents of profit this year.

Returned to shareholders
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises3 years

Growth
+11.8% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+12.0%
+11.8%
+11.7%
+9.3%
Net income
+9.3%
+6.2%
EPS, diluted
+4.1%
+2.7%
Returned to shareholders
−7.8%
−9.6%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
Shares outstanding, FY2025
Change, 5 years
Change, 10 years

A share split breaks the comparison across the period, so we leave it out.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 884.8M
total assets, end of FY2025
Total assetsUSD 884.8M
EquityUSD 448.2M
CashUSD 64.9M
Gross debtUSD 215.1M
Net debtUSD 150.2M
Current ratio3.53×

Net debt stands at 34% of equity.

History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.4
0.4
0.4
0.3
0.3
0.3
0.3
0.3
0.2
0.2
0.1
0.1
0.1
0.1
0.1
0.1
0.1
Operating income $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
EBITDA $B
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
EPS, diluted $
0.21
−0.32
−0.75
−0.48
−0.38
−0.44
0.05
−0.08
0.11
0.32
0.14
0.25
0.57
0.28
0.26
0.14
0.30
Dividend / sh $
·
·
·
·
·
·
0.00
0.00
0.00
0.00
0.12
0.12
0.11
0.05
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
85
45
18
17
·
·
·
ROE %
2.7
−4.8
−10.8
−6.6
−4.7
−5.4
0.6
−1.0
1.5
5.9
2.6
5.0
11.9
6.4
6.3
3.5
7.9
Shares out B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
66 of 66
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed